Beam Therapeutics
AWARDS
NEWS
Around 40% of Pfizer’s portfolio was realized through partnerships, and Monday, the pharma giant announced three more collaborative deals.
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
More than $170 million was paid out for drugs that manufacturers voluntarily withdrew from the market after subsequent trials showed no benefit in overall survival.
Biopharma companies recognized that developing a therapy is merely the beginning of what is needed to connect patients with sickle cell disease to next-level therapies.
The company’s technology aims to precisely search out genetic mutations at their precise genome location, limiting concerns about toxicities or unwanted cellular changes.
Beam Therapeutics has recently unveiled a new CRISPR base editing tool to target sickle cell mutations, a promising approach that holds substantial clinical value for patients with these blood disorders.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia.
Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday.
JOBS
IN THE PRESS